Skip to main content
. 2019 Jan 21;10(3):526–532. doi: 10.1111/1759-7714.12969

Figure 2.

Figure 2

Frequency of best overall response to immune checkpoint inhibitors in patients with non‐small cell lung cancer. (a) Frequency of best overall response to immune checkpoint inhibitor treatment among all patients (n = 40). (b) Frequency of best overall response to immune checkpoint inhibitor treatment among all patients with constipation (n = 20). (c) Frequency of best overall response to immune checkpoint inhibitor treatment across all patients without constipation (n = 20). CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.